Form 4: Coeptis Therapeutics Director Tara DeSilva Granted Stock Options

Director Tara DeSilva received a grant of 5,700 non-qualified stock options under the 2022 equity incentive plan.

Summary

• On March 4, 2025, Tara DeSilva, a director of Coeptis Therapeutics Holdings, Inc., was granted 5,700 non-qualified stock options.
• These options were granted under the company's 2022 equity incentive plan.
• The exercise price of the options is $10.56, which is equal to the company's stock price on the Nasdaq Capital Market on the day of the grant.
• The options vest over one year in four equal installments, starting on March 31, 2025, and ending on December 31, 2025.
• The options expire ten years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grant of options aligns the director's interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The director's future compensation is tied to the company's stock performance through these options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry, often used to incentivize executives and align their interests with shareholders.
• The vesting schedule of one year with quarterly installments is fairly typical.
• Comparable companies in the biotech sector, such as BioNTech or Moderna, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the director to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates